Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yerushalmy-Feler Anat, Spencer Elizabeth A, Dolinger Michael T, Suskind David L, Mitrova Katarina, Hradsky Ondrej, Conrad Máire A, Kelsen Judith R, Uhlig Holm H, Tzivinikos Christos, Ancona Silvana, Wlazlo Magdalena, Hackl Lukas, Shouval Dror S, Bramuzzo Matteo, Urlep Darja, Olbjorn Christine, D'Arcangelo Giulia, Pujol-Muncunill Gemma, Yogev Dotan, Kang Ben, Gasparetto Marco, Rungø Christine, Kolho Kaija-Leena, Hojsak Iva, Norsa Lorenzo, Rinawi Firas, Sansotta Naire, Magen Rimon Ramit, Granot Maya, Scarallo Luca, Trindade Eunice, Velasco Rodríguez-Belvís Marta, Turner Dan, Cohen Shlomi
Аннотация
METHODS: In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction.
RESULTS: One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3-17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologics. At the end of the 8-week induction period, clinical response, clinical remission, and corticosteroid-free clinical remission (CFR) were observed in 84%, 62%, and 56% of the children, respectively. Normal C-reactive protein and fecal calprotectin (FC) <150 mcg/g were achieved in 75% and 50%, respectively. Combined CFR and FC remission was observed in 18/46 (39%) children with available data at 8 weeks. Adverse events were recorded in 37 children, including 1 serious AE of an appendiceal neuroendocrine tumor. The most frequent AEs were hyperlipidemia (n = 13), acne (n = 12), and infections (n = 10, 5 of whom with herpes viruses).
CONCLUSIONS: Upadacitinib is an effective induction therapy for refractory pediatric UC and IBD-U. Efficacy should be weighed against the potential risks of AEs.